Mental Health Repository

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.

Journal: EClinicalMedicine

Volume: 71

Issue:

Year of Publication:

Abstract summary

The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic's start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020-2022).The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival.Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases.Not applicable.

Authors & Co-authors: Salmanton-García Marchesi Farina Weinbergerová Itri Dávila-Valls Martín-Pérez Glenthøj Hersby Gomes da Silva Nunes Rodrigues López-García Córdoba Bilgin Falces-Romero El-Ashwah Emarah Besson Kohn Van Doesum Ammatuna Marchetti Labrador Zambrotta Verga Jaksic Nucci Piukovics Cabirta-Touzón Jiménez Arellano Espigado Blennow Nordlander Meers van Praet Aiello Garcia-Vidal Fracchiolla Sciumè Seval Žák Buquicchio Tascini Gräfe Schönlein Adžić-Vukičević Bonuomo Cattaneo Nizamuddin Čerňan Plantefeve Prin Szotkovski Collins Dargenio Petzer Wolf Čolović Prezioso Valković Passamonti Méndez Sili Vena Bavastro Limongelli Duarte Ledoux Cvetanoski Stojanoski Machado Batinić Magliano Biernat Pantić Poulsen Cuccaro Del Principe Kulasekararaj Ormazabal-Vélez Busca Demirkan Ijaz Klimko Stoma Khostelidi Fernández Omrani Bergantim De Jonge Fouquet Navrátil Abu-Zeinah Samarkos Maertens De Ramón Guidetti Magyari González-López Lahmer Finizio Ali Pinczés Lavilla-Rubira Romano Merelli Delia Calbacho Meletiadis Antić Hernández-Rivas Marques de Almeida Al-Khabori Hoenigl Tisi Khanna Barać Eisa Di Blasi Liévin Miranda-Castillo Bahr Lamure Papa Yahya Aujayeb Novák Erben Fernández-Galán Ribera-Santa Susana Rinaldi Fazzi Piedimonte Duléry Gonzaga Soto-Silva Sapienza Serris Drgoňa Groh Serrano Gavriilaki Tragiannidis Prattes Coppola Otašević Mladenović Mitrović Mišković Jindra Zompi Sacchi Krekeler Infante García-Bordallo Çolak Mayer Nygaard Hanáková Ráčil Bonanni Koehler Rahimli Cornely Pagano

Study Outcome

Statistics

Citations : Vijenthira A., Gong I.Y., Fox T.A., et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
Authors : 167

Identifiers

Doi : 102553
SSN : 2589-5370

Study Population

Male,Female

Mesh Terms

Other Terms

COVID-19;Haematological malignancy;ICU;Immunosuppression;Vaccination

Study Design

Study Approach

Country of Study

Mali

Publication Country

England